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Introduction Results
Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in 
childhood and adolescence. RMS rarely occurs in adults, but the outcome is 
significantly worse. Most adult patients with advanced RMS die because their 
cancer exhibits or develops resistance to available therapies. Chemotherapy 
treatment for RMS includes Doxorubicin, a DNA intercalating agent and 
topoisomerase II inhibitor, and Vincristine, a mitosis inhibitor. 
Histologically, RMS is classified into two main subtypes, embryonal (ERMS) and 
alveolar (ARMS). ARMS tumors typically harbor chromosomal translocations 
resulting in the expression of PAX3- or PAX7-FOXO1 fusion proteins. ERMS tumors 
exhibit a much wider range of genetic abnormalities.  The fact that RMS of the 
same subtype may have significant difference in clinical behavior has been well 
recognized. Previously, we have shown that RMS cell lines propagated in vitro are 
heterogeneous with respect to expression of Myoblast determination protein 1 
(MyoD1) and Noggin (Nog). Importantly, MyoD+/Nog+ cells have shown higher 
levels of chemoresistance to Vincristine and Doxorubicin than MyoD negative cells 
in part to upregulation of anti-apoptotic genes Gli-1 and BcL2 (Dawson et al 2020). 
Hypothesis: 
We hypothesize that these Chemoresistant MyoD+/Nog+ cells are able to
reconstitute tumor heterogeneity when grown in vivo.
Figure 2. Flow cytometry data demonstrates tumor heterogenicity as well as chemoresistance of 
MyoD+Nog-,  MyoD+Nog+ and MyoD-Nog+ subpopulations to the two primary chemotherapeutic 
agents used to treat the disease, doxorubicin and vincristine. MyoD+Nog+ subpopulation exhibited 
the highest resistance to chemotherapy than MyoD- cells to both drugs with 2.5-5.9-fold increase in 
its fraction among live survived ERMS cells, in comparison to the composition of non-treated cells. 
(panel A). Importantly, cytotoxic treatment with both drugs did not stop cell proliferation of drug-
resistant cells but just slowed -down their proliferation rate (panel B). 
Material and Methods
Conclusions
Figure 3. MYOD1+ NOG+ cells express the highest 
levels of antiapoptotic BCL2 protein among other 
cells in the RD and A-204 cultures. Median 
fluorescence intensity (MFI) of BCL2 protein in 
MYOD1/NOG cell subpopulations of RD (left plot) 
and A-204 (right plot) cell lines. Data represented 
as ratio of BCL2 MFI of MYOD1+ NOG+ cells and 
MYOD1- NOG+ cells to BCL2 MFI of MYOD1- NOG-
cells (change in folds), (mean +/- standard 
deviation, N=9). ∗p<0.05, ∗∗p<0.01. Statistical 
significance determined by ANOVA with Turkey’s 
multiple comparison test). 
Cell culture and treatment: Human ERMS cell lines RD (ATCC CCL-136) and A204 
were cultured in DMEM media supplemented with 10% FCS, 1% antibiotic. Upon 
reaching 70-80% confluency, cells were treated with either 10nM Vincristine, 1µM 
Doxorubicin, or control medium (just culture medium) and incubated for 96 hours. 
Dead (detached) cells were then removed by rinsing cells with PBS and live 
adherent cells were harvested by treating cells with 0.25% trypsin/EDTA at 37oC. 
In-vivo murine model: Following in vitro drug treatment for 4 days, cells 
underwent a 3-day washout period. Live adherent cells were harvested, mixed 
with Matrigel (1:1) and subcutaneously injected into severe combined immune 
deficiency (SCID) mice (105 cells per injection). Tumors were harvested at 8 weeks 
time point.
Sample preparation and staining: Tumor single cell suspensions were prepared 
by mechanical disruption and Collagenase/DNase I digestion of tumor 
tissues. Then tumor cells and ERMS cells growing in vitro were fixed and 
permeabilized using Transcription factor buffer set (BD Biosciences) and stained 
with panels of fluorochrome-labeled antibodies to the following markers: MyoD1, 
Noggin and Bcl2.
In some experiments, cell proliferation assays were conducted using CellTrace
Violet cell proliferation kit according to the manufacturer’s protocol (Invitrogen). 
Briefly, RMS cells were incubated in 5 uM of dye in PBS solution, washed, seeded 
into 6-well plates at 0.4x106 cells per well and cultured for 4 days.
Flow Cytometry: Stained samples were run on 8-colors Stratedigm S1000EX 
cytometer and analyzed using CellCapture software (Stratedigm). The same type of 
cells stained with non-specific isotype controls were used to set gates for positive 
vs negative subpopulations. 
Figure 4. Flow cytometry analysis demonstrates following 8 weeks of tumor growth in 
SCID mice there is no significant difference between in cell composition of tumors 
initiated by drug treated ERMS cells when compared to tumors initiated by injection of 
non-treated ERMS cells. Two independent experiments were performed using the same 
protocol. The first experiment (4-A) was done with both vincristine and doxorubicin 
treated cells, however high level of doxorubicin autofluorescence limited its usage for 
flow analysis, therefore the second experiment (4-B) was done only with vincristine. Each 
plot represent individual tumor/mouse. Isotype control, account for stain 
autofluorescence. 
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Tumor heterogeneity and composition in response 
to chemotherapy 
Drug resistant ERMS cells growing in SCID 
mice restore original tumor composition
Figure 1.  A key to reading the flow cytometry data as 
reference for the post.  The plotted dots represent the cells 
passed through the flow cytometry. They are stained for 
identification of the markers MyoD and Noggin. Which 
quadrant they lie on, demarcated by the green line, 
represents which markers the cells expressed as detected 
by flow cytometry. 
MyoD+/Nog+ cells show highest levels of 
anti-apoptotic Bcl2 gene expression 
➢ MyoD+/Nog+ increase expression of antiapoptotic proteins and 
are able to confer some degree of chemoresistance. 
➢ These remaining MyoD+/Nog+ cells are also able to restore tumor 
heterogeneity similar to that composition of the original tumor 
composition seen in the non-treated tumors .
➢ MyoD+/Nog+ are able to restore their proliferation potential. 
➢ This could be the basis for a mechanism partially explaining the 
rebound tumors and metastasis that occur in adult RMS patients 
after treatment. 
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